Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Extends Research Deal with UBC, AlCana

Premium

Alnylam Pharmaceuticals said this week that it has extended its lipid delivery-technology collaboration with the University of British Columbia and Canadian firm AlCana Technologies for a third year.

The research collaboration is funded by Alnylam and the work will be conducted by scientists at UBC and AlCana.

Under the terms of the research alliance, which was forged in 2009, Alnylam has the exclusive rights to all new inventions in the RNAi field, as well as rights to sublicense any resulting intellectual property to Alnylam's current and future partners.

As part of the original agreement, Tekmira Pharmaceuticals receives the rights to use any new AlCana/UBC inventions for its own RNAi therapeutic programs licensed under Alnylam intellectual property.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.